Nov 22 (Reuters) - Halozyme Therapeutics said on Friday it had withdrawn its proposal to acquire Evotec SE
for 2 billion euros ($2.09 billion) after the German drug developer was unwilling to engage in discussions.
($1 = 0.9587 euros)
(Reporting by Sriparna Roy in Bengaluru; Editing by Devika Syamnath)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments